Zhejiang Conba Pharmaceutical Co (SHSE:600572) Tariff Resilience Score: 0/10 (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600572 Zhejiang Conba Pharmaceutical Co Ltd SHSE:600572
73 GF Score
Price ¥4.34
GF Value ¥5.56
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Zhejiang Conba Pharmaceutical Co Tariff Resilience Score?

Zhejiang Conba Pharmaceutical Co has the Tariff Resilience Score of 0, which implies that the company might have .

Zhejiang Conba Pharmaceutical Co has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Zhejiang Conba Pharmaceutical Co might have .

Zhejiang Conba Pharmaceutical Co  (SHSE:600572) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Zhejiang Conba Pharmaceutical Co Tariff Resilience Score Related Terms

SHSE:600572
73GF Score
Zhejiang Conba Pharmaceutical Co Ltd SHSE:600572
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zhejiang Conba Pharmaceutical Co (SHSE:600572) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥4.34 is trading 21.9% below its estimated GF Value™ of ¥5.56. GuruFocus considers Zhejiang Conba Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:600572:

  • Tariff Resilience Score: 0
  • GF Value™: ¥5.56 vs. price of ¥4.34 (21.9% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the SHSE:600572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Conba Pharmaceutical Co Business Description

Address No. 568 Binkang Road, New and High-Technology Development Zone, Binjiang District, Zhejiang, Hangzhou, CHN, 310052
Zhejiang Conba Pharmaceutical Co Ltd operates as a pharmaceutical company in China. It offers traditional Chinese medicines, botanical extracts, chemical medicines, chemical raw medicines, health foods, common foods, prepared drugs in pieces, and commodities. It provides its products under the Conba, Prostate Plus, Zhenshiming, Tianbaoning, Alocin, Xitao, Yuanbang, Baby, and Omeprazole names.
73GF Score

Get the complete analysis for SHSE:600572

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥4.34
Price
¥5.56
GF Value